Answers are grounded in this paper and cite their sources.
Background Candida empyema thoracis is rare, and evidence to guide antifungal choice, dose, and duration remains limited. Most cases arise after thoracoabdominal procedures, esophageal or gastrointestinal disruption, or marked immunosuppression. Candida recovered from respiratory secretions often reflects colonization; repeated isolation from freshly sampled pleural pus carries a different diagnostic weight. Case presentation A 55-year-old man with poorly controlled type 2 diabetes and hypertension presented with 10 days of cough and purulent sputum. He was afebrile but tachycardic and hypoxemic. Computed tomography showed a right-sided cavitary pulmonary lesion with an air-fluid level, compatible with lung abscess, and a loculated pleural air-fluid collection. Hypersensitive C-reactive protein was 180.6 mg/L and procalcitonin was 3.10 ng/mL. Thoracentesis yielded milky-brown purulent fluid with 93.70% polymorphonuclear leukocytes. Candida albicans was recovered from pleural fluid on two separate occasions; the second isolate was susceptible to fluconazole and other tested antifungals. Candida albicans was also detected in sputum and bronchoalveolar lavage fluid, while bronchoalveolar lavage metagenomic sequencing detected both Candida albicans and Staphylococcus aureus . Serum (1,3)-beta-D-glucan and galactomannan were negative. Antibacterial therapy and pleural drainage were followed by substantial improvement in inflammatory markers before antifungal treatment was initiated. CRP decreased to 1.88 mg/L and procalcitonin to 0.04 ng/mL by April 9. Because Candida albicans was repeatedly isolated from pleural fluid, fluconazole was added on April 10 for culture-confirmed Candida empyema. Continued drainage, antibacterial therapy, glycemic management, and an approximately six-week course of fluconazole were followed by clinical recovery and near-complete radiographic resolution. Conclusion This case demonstrates that culture-proven Candida empyema may occur in a patient without classic surgical or gastrointestinal risk factors and may remain afebrile with negative serum fungal biomarkers. Repeated recovery of Candida from freshly obtained pleural pus should not be dismissed as airway colonization. Early pleural source control, species identification with susceptibility testing, targeted antifungal therapy, and correction of modifiable host factors should be considered key components of management. Possible bacterial coinfection and improvement before antifungal treatment limit attribution of the clinical response to antifungal therapy alone.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: